{"entity":{"id":"nct04036682","kind":"trial","name":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","aka":["REZILIENT1"],"tldr":"A phase 1/2 trial of Zipalertinib in non-small-cell lung cancer and small-cell lung cancer, run by Cullinan Therapeutics Inc., active and no longer recruiting.","summary":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04036682 by Cullinan Therapeutics Inc., with 284 participants planned, started 2019-10-31 and due to reach its primary completion in 2025-10-13. Interventions recorded: CLN-081. Conditions listed: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04036682","url":"https://clinicaltrials.gov/study/NCT04036682"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zipalertinib"],"companies":["cullinan-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04036682-j-clin-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04036682","phase":"1/2","setting":"A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy","sponsor":"Cullinan Therapeutics Inc.","participation":[{"nct":"NCT04036682","source":"https://clinicaltrials.gov/study/NCT04036682","fetchedAt":"2026-10-07T16:53:12.810Z","studySha256":"2127cc609cf7e33bca66e3c8853ede415dc377811da593fbb75833641b3034a4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-17","leadSponsor":"Cullinan Therapeutics Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":284,"enrolmentType":"ESTIMATED","siteCount":64,"recruitingSiteCount":0,"countries":["Hong Kong","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Taiwan","United States"]}],"started":"2019-10-31","startedType":"actual","enrolled":284,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04036682/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/"}],"company":[{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/"}],"paper":[{"id":"paper-nct04036682-j-clin-oncol-2025","kind":"paper","name":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab","route":"/key-papers/paper-nct04036682-j-clin-oncol-2025/"}]}}